Financial Comparison: Protara Therapeutics (NASDAQ:TARA) versus Brickell Biotech (NASDAQ:BBI)

Protara Therapeutics (NASDAQ:TARAGet Rating) and Brickell Biotech (NASDAQ:BBIGet Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Earnings and Valuation

This table compares Protara Therapeutics and Brickell Biotech’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protara Therapeutics N/A N/A -$47.25 million ($3.35) -0.98
Brickell Biotech $400,000.00 16.67 -$39.47 million ($13.52) -0.17

Brickell Biotech has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Brickell Biotech, indicating that it is currently the more affordable of the two stocks.


This table compares Protara Therapeutics and Brickell Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protara Therapeutics N/A -24.86% -23.36%
Brickell Biotech -643.48% -156.10% -128.23%

Risk & Volatility

Protara Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Brickell Biotech has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Protara Therapeutics and Brickell Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protara Therapeutics 0 0 1 0 3.00
Brickell Biotech 0 1 1 0 2.50

Protara Therapeutics presently has a consensus price target of $23.00, suggesting a potential upside of 602.48%. Given Protara Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Protara Therapeutics is more favorable than Brickell Biotech.

Institutional and Insider Ownership

50.3% of Protara Therapeutics shares are owned by institutional investors. 15.2% of Protara Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Brickell Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Protara Therapeutics beats Brickell Biotech on 9 of the 12 factors compared between the two stocks.

About Protara Therapeutics

(Get Rating)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

About Brickell Biotech

(Get Rating)

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with's FREE daily email newsletter.